- Home
- SNTI vs APM Comparison
SNTI vs APM Comparison
Compare SNTI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- APM
- Stock Information
- Founded
- SNTI 2016
- APM 2010
- Country
- SNTI United States
- APM United Kingdom
- Employees
- SNTI N/A
- APM N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- APM Health Care
- Exchange
- SNTI Nasdaq
- APM Nasdaq
- Market Cap
- SNTI 10.4M
- APM 9.8M
- IPO Year
- SNTI N/A
- APM 2018
- Fundamental
- Price
- SNTI $2.15
- APM $0.68
- Analyst Decision
- SNTI
- APM
- Analyst Count
- SNTI 0
- APM 0
- Target Price
- SNTI N/A
- APM N/A
- AVG Volume (30 Days)
- SNTI 16.0K
- APM 36.0K
- Earning Date
- SNTI 11-26-2024
- APM 12-20-2024
- Dividend Yield
- SNTI N/A
- APM N/A
- EPS Growth
- SNTI N/A
- APM N/A
- EPS
- SNTI N/A
- APM N/A
- Revenue
- SNTI N/A
- APM $431,378.00
- Revenue This Year
- SNTI $254.47
- APM $157,729.10
- Revenue Next Year
- SNTI $169.66
- APM N/A
- P/E Ratio
- SNTI N/A
- APM N/A
- Revenue Growth
- SNTI N/A
- APM N/A
- 52 Week Low
- SNTI $1.52
- APM $0.64
- 52 Week High
- SNTI $7.43
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- SNTI 44.66
- APM 13.95
- Support Level
- SNTI $2.12
- APM $1.21
- Resistance Level
- SNTI $2.40
- APM $1.37
- Average True Range (ATR)
- SNTI 0.16
- APM 0.12
- MACD
- SNTI 0.02
- APM -0.03
- Stochastic Oscillator
- SNTI 13.98
- APM 4.89
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.